[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @YHdjdhd YHsudhd Hdjdhd YHsudhd Hdjdhd posts on X about $bntx, $bmy, $mgx, remarkable the most. They currently have XX followers and X posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1489323641770856453/interactions)  - X Week XXXXX +29% - X Month XXXXX -XXX% - X Months XXXXXXXXXX +43,532% - X Year XXXXXXXXXX +473,362% ### Mentions: X [#](/creator/twitter::1489323641770856453/posts_active)  - X Week X +33% - X Month XX -XX% - X Months XX +880% - X Year XX +179% ### Followers: XX [#](/creator/twitter::1489323641770856453/followers)  - X Week XX +8.70% - X Month XX +6.40% - X Months XX +39% - X Year XX +285% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1489323641770856453/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XX% **Social topic influence** [$bntx](/topic/$bntx) #1, [$bmy](/topic/$bmy) #12, [$mgx](/topic/$mgx) 12.5%, [remarkable](/topic/remarkable) XXXX% **Top accounts mentioned or mentioned by** [@rnaianalyst](/creator/undefined) [@adamfeuerstein](/creator/undefined) [@auditor112017](/creator/undefined) [@michaelmaiello](/creator/undefined) [@mortysoley](/creator/undefined) [@geneinvesting](/creator/undefined) [@alexfabra339670](/creator/undefined) [@3primeanalytica](/creator/undefined) [@a_may_md](/creator/undefined) **Top assets mentioned** [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) ### Top Social Posts Top posts by engagements in the last XX hours "@RNAiAnalyst Does this news shift your take on $mgx" [X Link](https://x.com/YHdjdhd/status/1995566390435315988) 2025-12-01T18:51Z XX followers, XXX engagements "New global Phase X data for pumitamig in TNBC look even stronger in detail: 1) PD-L1-negative pts respond almost as well as PD-L1-positive (uORR XXXX% vs 70.6%) a huge unmet need. 2) ctDNA clearance is remarkable (median XXX% at C3D1; XX% at XX mg/kg) $BNTX $BMY" [X Link](https://x.com/YHdjdhd/status/1998386013941444784) 2025-12-09T13:35Z XX followers, XX engagements "Key new insights from the ROSETTA Breast-01 Phase X design: X The trial focuses on PD-L1-negative TNBC a population with no effective IO standard and major commercial upside. X Dual primary endpoints (OS + PFS by BICR) in a 558-pt double-blind global trial $BNTX $BMY" [X Link](https://x.com/YHdjdhd/status/1998386684564558211) 2025-12-09T13:38Z XX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@YHdjdhd YHsudhd Hdjdhd
YHsudhd Hdjdhd posts on X about $bntx, $bmy, $mgx, remarkable the most. They currently have XX followers and X posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX +29%
- X Month XXXXX -XXX%
- X Months XXXXXXXXXX +43,532%
- X Year XXXXXXXXXX +473,362%
Mentions: X #
- X Week X +33%
- X Month XX -XX%
- X Months XX +880%
- X Year XX +179%
Followers: XX #
- X Week XX +8.70%
- X Month XX +6.40%
- X Months XX +39%
- X Year XX +285%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence stocks XX%
Social topic influence $bntx #1, $bmy #12, $mgx 12.5%, remarkable XXXX%
Top accounts mentioned or mentioned by @rnaianalyst @adamfeuerstein @auditor112017 @michaelmaiello @mortysoley @geneinvesting @alexfabra339670 @3primeanalytica @a_may_md
Top assets mentioned Bristol-Myers Squibb Co (BMY)
Top Social Posts
Top posts by engagements in the last XX hours
"@RNAiAnalyst Does this news shift your take on $mgx"
X Link 2025-12-01T18:51Z XX followers, XXX engagements
"New global Phase X data for pumitamig in TNBC look even stronger in detail: 1) PD-L1-negative pts respond almost as well as PD-L1-positive (uORR XXXX% vs 70.6%) a huge unmet need. 2) ctDNA clearance is remarkable (median XXX% at C3D1; XX% at XX mg/kg) $BNTX $BMY"
X Link 2025-12-09T13:35Z XX followers, XX engagements
"Key new insights from the ROSETTA Breast-01 Phase X design: X The trial focuses on PD-L1-negative TNBC a population with no effective IO standard and major commercial upside. X Dual primary endpoints (OS + PFS by BICR) in a 558-pt double-blind global trial $BNTX $BMY"
X Link 2025-12-09T13:38Z XX followers, XX engagements